Literature DB >> 30961938

Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance.

Jordan D Awerbach1, Kathryn A Stackhouse2, Joanne Lee3, Talal Dahhan4, Kishan S Parikh1, Richard A Krasuski5.   

Abstract

BACKGROUND: The clinical characteristics, hemodynamic changes and outcomes of lung disease-associated pulmonary hypertension (LD-PH) are poorly defined.
METHODS: A prospective cohort of PH patients undergoing initial hemodynamic assessment was collected, from which 51 patients with LD-PH were identified. Baseline characteristics and long-term survival were compared with 83 patients with idiopathic pulmonary arterial hypertension (iPAH).
RESULTS: Mean age (±standard deviation) of LD-PH patients was 64 ± 10 years, 30% were female and 78% were New York Heart Association class III-IV. The LD-PH group was older than the iPAH group (64 ± 10 vs 56 ± 18 years, respectively, P = 0.003) with a lower percentage of women (30% vs 70%, P = 0.007). LD-PH patients had smaller right ventricular sizes (P = 0.02) and less tricuspid regurgitation (P = 0.03) by echocardiogram, and lower mean pulmonary arterial pressures (mPAP) (P = 0.01) and pulmonary vascular resistance (PVR) (P = 0.001) at catheterization. Despite these findings, mortality was equally high in both groups (P = 0.16). 5-year survival was lower in patients with interstitial lung disease compared to those with obstructive pulmonary disease (P = 0.05). Among the LD-PH population, those with mild to moderately elevated mPAP and those with PVR <7 Wood units demonstrated significantly improved survival (P = 0.04 and P = 0.001, respectively). Vasoreactivity was not associated with improved survival (P = 0.64). A PVR ≥7 Wood units was associated with increased risk of mortality (hazard ratio (95% confidence interval), 3.59 (1.27-10.19), P = 0.02).
CONCLUSIONS: Despite less severe PH and less right heart sequelae, LD-PH has an equally poor clinical outcome when compared to iPAH. A PVR ≥7 Wood units in LD-PH patients was associated with 3-fold higher mortality.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30961938     DOI: 10.1016/j.rmed.2019.03.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  1 in total

1.  Clinical insights into pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  Daniel P Cook; Meng Xu; Victoria L Martucci; Jeffrey S Annis; Melinda C Aldrich; Anna R Hemnes; Evan L Brittain
Journal:  Pulm Circ       Date:  2022-01-03       Impact factor: 2.886

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.